国际眼科杂志Issue(5)：797-801,5.DOI:10.3980/j.issn.1672-5123.2014.05.03
比较雷珠单抗和贝伐珠单抗对新生血管AMD的疗效
Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
Huseyin Serdarogullari 1Muzaffer Ozturk 2Umur Kayhan 1Selim Bolukbasi 1Burak Erden 1Mustafa Elcioglu1
作者信息
- 1. 土耳其，伊斯坦布尔，奥克梅达尼教学研究医院眼科
- 2. 土耳其，伊斯坦布尔，顿尼亚Goz Hastanesi 世界眼科医院
- 折叠
摘要
Abstract
AIM:To compare the efficacy of intravitreal ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) using a pro re nata ( PRN) treatment regimen. <br> METHODS: A total of 63 eyes ( 35 eyes treated with ranibizumab and 28 eyes treated with bevacizumab) of 63 patients with newly diagnosed neovascular AMD were analyzed and compared retrospectively. Outcomes included comparison of best - corrected visual acuity ( BCVA ) and central foveal thickness ( CFT ) after ranibizumab or bevacizumab treatment at 12mo follow-up. Two-tailed t-tests and one-way ANOVA were used to compare mean changes in BCVA and CFT for different groups. <br> RESULTS: Thirty-five eyes treated with ranibizumab and 28 eyes treated with bevacizumab were enrolled and completed 12mo follow - up. At 12mo, mean BCVA increased by 0. 1logMAR with ranibizumab treatment;however BCVA decreased by 0. 06logMAR with bevacizumab treatment (P= 0. 01). A gain of at least 0.3logMAR in BCVA was observed in 13 eyes ( 37%) treated with ranibizumab and in 4 eyes ( 14%) treated with bevacizumab. Mean CFT reduced by 41. 6μm and 8. 1μm in the ranibizumab and bevacizumab groups, respectively (P=0. 003). The mean number of injections per eye was 4. 46 with ranibizumab and 4. 11 with bevacizumab (P>0. 05). <br> CONCLUSION: Intravitreal ranibizumab yielded better visual and anatomical results than bevacizumab. However, randomized long-term clinical trials are needed to draw conclusions about efficacy and safety of the two drugs.关键词
年龄相关性黄斑变性/抗血管内皮生长因子治疗/雷珠单抗/贝伐珠单抗/脉络膜新生血管Key words
age-related macular degeneration/anti-VEGF therapy/ranibizumab/bevacizumab/choroidal neovascularization引用本文复制引用
Huseyin Serdarogullari,Muzaffer Ozturk,Umur Kayhan,Selim Bolukbasi,Burak Erden,Mustafa Elcioglu..比较雷珠单抗和贝伐珠单抗对新生血管AMD的疗效[J].国际眼科杂志,2014,(5):797-801,5.
